Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
The Research Council of Norway and Norway’s research institutions are providing a total of NOK 1 billion to 46 FRIPRO Toppforsk projects (FRIPRO - "Frie prosjektmidler"). Each project will receive NOK 15–25 million over a four-to-five-year period.
FRIPRO is an open competitive arena for all research areas and disciplines, where there are no thematic guidelines and no requirements relating to the applicability or immediate utility of the research. The competition in FRIPRO is tough, and only the best researchers with particularly good projects and very well-written proposals have a chance at succeeding.
University of Oslo and Oslo University Hospital based research groups led by Ragnhild A. Lothe from the Department of Molecular Oncology and Michael Bretthauer from the Department of Transplantation Medicine are among the successful applicants.
The ongoing scientific activities of Camilla Raiborg from Harald Stenmark's group at the Department of Molecular Cell Biology have recently been presented on the major Norwegian popular science web site forskning.no, as well as on the home page of the Norwegian Cancer Society. Raiborg is heading the project group "Protein dynamics in tumor suppressor pathways".
An article from the Department of Cardiology entitled "Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial" has recently been published online in Lancet (journal impact factor 39.2)
The results are discussed in the Lancet Comment section, and the research was given front page attention in the paper edition of the major Norwegian newspaper Aftenposten on January 20th. The article is first-authored by PhD stipendiate Nicolai Kloumann Tegn, while Bjørn Bendz (photo) is senior author.
Susanne Lorenz has together with her colleagues at the Department for Tumor Biology and the Genomics Core Facility recently published an extensive genomic study of osteosarcoma in Oncotarget (journal impact factor 6.4). This study combined whole genome and transcriptome sequencing to unscramble the genomic chaos and its consequences.
What have we achieved since 2012 in risk prediction, early diagnosis, progression, and therapy?
This Symposium is part of an annual series that Prof. Enrico Mihich has been organizing in collaboration with Hans-Peter Huber and Kurt S. Zänker at the Fritz Bender Foundation, Munich, Germany and a host institution.
In 2012 this symposium took place in Oslo, Norway with the Institute for Cancer Research at the Norwegian Radium Hospital Oslo University Hospital and the Radium Hospital Foundation as hosts. It was decided at that meeting that a second symposium with the same program and speakers should take place 3-4 years later with the focus on what have we achieved since 2012. Hence the follow-up meeting will take place in Oslo in May 2016.
The symposium is now open for registration and abstract submission.
Andreas Midbøe Hoff, who recently defended his PhD thesis, has together with colleagues at Department of Molecular Oncology discovered novel fusion genes in testicular germ cell tumours. The results are published in the current issue of Cancer Research (journal impact factor 9.28)
Åslaug Helland and coworkers have been part of a study where lung cancer tumours have been reduced in size after giving the patients drugs previously used in treatment of malignant melanomas. These studies have been performed due to certain similarities between lung cancer and melanoma cells. The research is part of an international clinical study where in total 40 lung cancer patients have been given the drugs dabrafenib and trametinib.
Before Christmas The Norwegian Cancer Society and the Norwegian Research Council distributed 56 million NOK to various innovation projects. These projects will develop products cancer patients are in need of. TTOs (Technololgy Transition Offices) and Inven2 are project leaders for most, and many of the researchers are affiliated to OUS.
One of the supported projects is led by Alicia Llorente from Kirsten Sandvig's group at the Department of Molecular Cell Biology at the Institute for Cancer Research.
The Norwegian Cancer Society has written an article about her project (in Norwegian).
Kirsten Sandvig recently received a new grant for work with biodegradable nanoparticles. Sandvig is heading the national competence building project in nanomedicine entitled “Biodegradable Nanoparticles in Cancer Diagnosis and Therapy”. She has now received a grant through INNO INDIGO which is an innovation-driven initiative for the development and integration of Indian and European research.
The goal of the new project is to develop biodegradable nanoparticles for cancer therapy (breast and colorectal). The work in Oslo will include testing of the nanoparticles on cells and in animal models, in close collaboration with Gunhild Mælandsmo, Kjersti Flatmark and Tore Skotland. The nanoparticles will be produced by groups in India and Belgium; the group in Belgium will also perform in vivo studies.
An article from Magnar Bjørås’ "Cellular responses to DNA damage" group at the Department of Microbiology has recently (December 29th) been published in “Cell Report” (journal impact factor 8.4).
The paper is entitled "Synergistic Actions of Ogg1 and Mutyh DNA Glycosylases Modulate Anxiety-like Behavior in Mice”. Monica D. Bjørge, Gunn A. Hildrestrand and Katja Scheffler are co-first authors, while Bjørås (photo) is senior author.
Filming live cancer cells
Jan 29, 2016
Elderly patients benefit from an early invasive strategy
Jan 20, 2016
Jan 19, 2016
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
The rights of children arriving in Europe
Lancet, 386 (10007), 1939-40
Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label randomised controlled trial
Lancet (in press)
More selected publications